Photo by taylor65s from unsplash
As yet, there are no randomized studies of chimeric antigen receptor (CAR) T-cell therapy versus standard therapy in patients with multiple relapsed follicular lymphoma. To provide early insight into comparative… Click to show full abstract
As yet, there are no randomized studies of chimeric antigen receptor (CAR) T-cell therapy versus standard therapy in patients with multiple relapsed follicular lymphoma. To provide early insight into comparative efficacy, Ghione et al used propensity scoring analysis on prespecified prognostic factors with standardized mortality weighting to match patients in the SCHOLAR-5 retrospective registry to those in the ZUMA-5 study of axicabtagene ciloleucel (axi-cel). These insights suggest superiority in response rate with axi-cel with longer times to the next treatment and improved progression-free and overall survival.
Journal Title: Blood
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!